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Transcriptomics and proteomics show that selenium
affects inflammation, cytoskeleton, and cancer
pathways in human rectal biopsies
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Daniel M. Commane,‡ Ramesh P. Arasaradnam,†,#,** Francis Mulholland,{ Anze Zupanic,*
John C. Mathers,‡,** and John Hesketh*,‡,§
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║Bioinformatics Support Unit, and **Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, United Kingdom; {Institute of
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ABSTRACT:Epidemiologic studieshighlight thepotential roleofdietaryselenium(Se) in colorectal cancerprevention.
Ourgoalwas to elucidatewhetherexpressionof factors crucial for colorectal homoeostasis is affectedbyphysiologic
differences in Se status. Using transcriptomics and proteomics followed by pathway analysis, we identified path-
ways affected by Se status in rectal biopsies from 22healthy adults, including 11 controlswith optimal status (mean
plasma Se = 1.43 mM) and 11 subjects with suboptimal status (mean plasma Se = 0.86 mM). We observed that 254
genes and 26 proteins implicated in cancer (80%), immune function and inflammatory response (40%), cell growth
andproliferation (70%), cellularmovement, andcelldeath (50%)weredifferentially expressedbetween the2groups.
Expression of 69 genes, including selenoproteinsW1 and K, which are genes involved in cytoskeleton remodelling
and transcription factor NFkB signaling, correlated significantly with Se status. Integrating proteomics and tran-
scriptomics datasets revealed reduced inflammatory and immune responses and cytoskeleton remodelling in the
suboptimal Se status group. This is the first study combining omics technologies to describe the impact of differ-
ences in Se status on colorectal expression patterns, revealing that suboptimal Se status could alter inflammatory
signaling and cytoskeleton inhuman rectalmucosa and so influence cancer risk.—Me´plan,C., Johnson, I. T., Polley,
A. C. J., Cockell, S., Bradburn, D. M., Commane, D. M., Arasaradnam, R. P., Mulholland, F., Zupanic, A., Mathers,
J. C.,Hesketh, J. Transcriptomics andproteomics show that seleniumaffects inflammation, cytoskeleton, and cancer
pathways in human rectal biopsies. FASEB J. 30, 2812–2825 (2016). www.fasebj.org
KEY WORDS: selenoprotein • NFkB • colorectal • cytokeratin • nutrigenomics
Low intake of the dietary antioxidant micronutrient sele-
nium (Se) is associated with increased risk of colorectal
adenoma and of colorectal cancer (CRC) mortality (1); for
example, in the double-blind, randomized, placebo-
controlled Nutrition Prevention Cancer Trial, there was a
significant (58%) reduction in CRC incidence in people
receiving 200 mg supplementary Se in the form of Se-
enriched yeast/d (2), and the strongest effect of Se
supplementation was observed in subjects within
the lowest tertile for plasma Se at the start of the trial
(,1.34 mM). In contrast, in the Women’s Health Ini-
tiative and Selenium and Vitamin E Cancer Prevention
Trial (SELECT) trials, no benefit of increased Se intake
was observed for individuals with high Se intakes
(3, 4). Recent data from a European Prospective In-
vestigation into Cancer and Nutrition (EPIC) cohort
revealed that, in most European countries, plasma Se
status is suboptimal and is associated with increased
risk of CRC in women (5). Moreover, evidence from
animal models showed that Se supplementation can
prevent chemically induced colorectal carcinogenesis
(6, 7). Taken together, these data support a role for Se
in reducing risk of CRC initiation and progression;
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however, the intake at which Se has cancer-preventive
properties and the mechanisms underlying its anti-
carcinogenic properties remain unclear.
The biologic actions of Se are thought to be mediated
largelyby selenoproteins inwhichSe is incorporated in the
form of the amino acid selenocysteine. Functional genetic
polymorphisms in selenoprotein genes (GPX4, SEPP1,
SELS, and GPX1) modulate risk of CRC or inflammatory
responses (8, 9), in combination with Se status (9). Sele-
noproteins are crucial in the biochemical pathways es-
sential for colorectal function, including redox control and
responses to inflammatory, oxidative, and endoplasmic
reticulum stress (10). For example, GPx4 expression was
necessary formitochondrial function andNFkB response to
TNFa in a human colorectal adenoma cell model (11, 12),
and Se intake affected mRNA mTOR, TNFa, and NF-kB
signalingpathways in the colonofmice fedamarginally Se-
deficientdiet (13).Thus, theprotective effect of Seappears to
bemediated through the role of selenoproteins inmolecular
pathways that help to maintain homeostasis when cells
experience oxidative and inflammatory challenges (9).
However, the effects of Se status on such pathways within
thehumancolorectal epitheliumremainpoorlyunderstood.
To identifykeyfactorsandpathwaysaffectedbySestatus,
we combined transcriptomics and proteomics in a compre-
hensive, unbiased analysis of rectal biopsy specimens from
healthy participants. For the first time, we have shown in
humans that differences in Se status within the physiologic
range affect global gene expression patterns in the human
rectum.WefoundthatSestatusaffected factors implicated in
inflammatory signaling, immune function, and cytoskeleton
remodelling. These findings provide insights into the mech-
anisms throughwhichSemay influence cancer risk andmay
help in the development of early biomarkers of disease risk.
MATERIALS AND METHODS
Study population and sample collection
A subgroup of 22 adultswho took part in the Biomarkers of Risk
of Colorectal Cancer (BORICC) study were recruited from pa-
tients attending for routine flexible sigmoidoscopy atWansbeck
General Hospital (14), but shown to be free of colorectal disease.
Ethics approval was granted by the Northumberland Local Re-
searchEthicsCommittee, andresearchgovernancewasobtained
from the Northumberland Healthcare Trust (NLREC2/2001).
Exclusion criteria included the presence or history of colonic
inflammation, colorectal cancers or polyps, or a strong family
history of colorectal cancer. Biopsies were performed in indi-
viduals who had no evidence of colorectal neoplasia or inflam-
matory bowel disease at endoscopy. Mucosal pinch biopsies
were obtained fromanatomically normalmucosa 10 cm from the
rectal verge, snap frozen in liquidnitrogen forproteomic analysis
orplaced immediately inRNAlater (ThermoFisher Scientific Life
Sciences, Paisley, United Kingdom) for transcriptomic analyses,
and stored at280°C. Plasma Se concentrationwas measured by
inductively coupled plasma mass spectrometry (MS).
RNA isolation and microarray analysis
RNA extraction was performed with Trizol (Thermo Fisher
Scientific Life Sciences), according to standard procedures.
Briefly, RNAlater was drained from the biopsy specimens
before they were submerged in 0.5 ml Trizol. After homoge-
nizing the tissues on ice, an additional 0.5 ml Trizol was
added, and samples were incubated for 5 min at room tem-
perature. Samples were centrifuged (10 min, 12,000 g, 4°C),
supernatants were extracted for 3minwith 0.2ml chloroform
per 0.2 ml Trizol) and centrifuged (15 min, 12,000 g, 4°C), and
the upper phase was precipitated in 70% EtOH prepared in
diethylpyrocarbonate-treated milliQ water (EMD–Millipore,
Billerica, MA, USA). Samples were purified on a PureLink
RNA cartridge (Thermo Fisher Scientific Life Sciences) and
eluted in RNase-DNase–free water. RNA integrity was de-
termined by capillary electrophoresis with a Bioanalyzer
Nano chip (Agilent Technologies, Stockport, United Kingdom)
before microarray analysis, using whole-genome HumanHT-12,
v3 single-color bead chips (Illumina, San Diego, CA, USA).
Microarray results were confirmed by real-time PCR; however,
because the biopsy specimens were very small, the amount of
RNAwas sufficient to confirmonly the expressionof 2genes and
a housekeeping control used to normalize the data.
Protein preparation and gel electrophoresis
Proteins were extracted from thawed tissue with a modified
ReadyPrep Sequential Extraction Kit (Bio-Rad, Hemel Hemp-
stead, United Kingdom), and the specimens were homogenized
with a hand-operated micropestle (Eppendorf, Hamburg,
Germany) before sonication in an ice-water bath for 10 min. The
samples were centrifuged, and aliquots of supernatants were
stored at280°C. Proteins were separated by 2-D electrophoresis
(15). Separation of proteins in the first dimensionwas performed
by isoelectric focusing (IEF), with 24 cm immobilized pH gradi-
ent strips (pH 4–7) run on an Ettan IPGphor bed (GEHealthcare,
Pittsburgh, PA, USA) with a step-n-hold protocol of 500 V for
0.5 kVh; a gradient of 1000 V for 0.8 kVh; a gradient of 8000 V for
13.5 kVh; anda step-n-hold of 8000V for 30.0 kVh at 20°C, giving
a total of 44.8kVh (8h49min)witha rate-limiting factor of 50mA.
After completion of IEF, the strips were stored at280°C. The 2-
dimensionprotein separationwas carried out on 1mmthick 10%
Duracryl homogenous gels [30% acrylamide with 0.65% N,N-
methylene bis-acrylamide cross-linker, 1.5 M Tris (pH 8.7–9.0),
3.6 mM SDS, 0.5 ml/L tetramethylethylenediamine, and 11 mM
ammoniumpersulfate, prepared in-house in 283 23 cmgel-plate
cassettes]. Electrophoresis conditions were set to give an top
voltage of 500 V, power of 20 W/gel, and a total run time of
;4.5 h. Gels were stained with SYPRO Ruby fluorescent stain
(Bio-Rad) and imaged with a Pharos FX Plus molecular imager
(Bio-Rad; 532 nm excitation laser and 605 nm emission filter at
100 mm resolution). Using Progenesis SameSpot software (Non-
linear Dynamics, Newcastle, United Kingdom), an experienced
operator aligned the gel images to a single reference image,
chosen for its overall quality and spot clarity, and protein spots
were quantified. At this stage, staining artifacts were removed
manually, and undetected double spots were corrected. Proteins
of interest were extracted and analyzed by usingmatrix-assisted
laser desorption/ionization time-of-flight (MALDI/ToF) MS.
In-gel trypsin digestion was performed with a ProGest Protein
Digester (Genomic Solutions, Ltd., London, United Kingdom).
After preincubation, the digestions were carried out at 37°C for
3 h, using 50 ng sequencing-grade porcine trypsin (5 ml/well;
Promega, Southampton, United Kingdom). The digests were
analyzedwith anUltraflexMALDI-ToF/ToFmass spectrometer
(Bruker Daltonics, Ltd., Coventry, United Kingdom). A 200 Hz
nitrogen laser was used to desorb/ionize the matrix/analyte
material, and ions were detected in positive ion reflectronmode.
Peptide masses obtained from the MALDI-ToF analysis were
searched against the Mass Spectrometry Data Base using the
Mascot peptide mass-fingerprint program (Matrix Science, Ltd.,
London, United Kingdom). The results gave a probability-based
SELENIUM TARGETS IN RECTAL MUCOSA 2813
 Vol.30,  No.8 , pp:2812-2825, August, 2016The FASEB Journal. 128.240.225.42 to IP www.fasebj.orgDownloaded from 
Mowse score of 210 p log(P ), where P is the probability that
the observed match is a random event. Under those parame-
ters, protein scores ,63 were considered statistically signifi-
cant (P , 0.05).
Transcriptomics and proteomics analysis
Rawgene expression datawere analyzedwith GeneSpring GX
11 (Agilent Technologies). Raw data were normalized with a
quantile algorithm, and the baseline was transformed to the
median of all samples. Those probes with a flag value of pre-
sent ormarginal in$80% of any of the experimental categories
were selected for further analysis. The R package RankProd
(Bioconductor; http://bioconductor.org/) was used to identify
differentially expressed genes. Genes were defined as differ-
entially expressed if the percentage of false positives in 1000
permutations of the Rank Products test was ,5% and the
change in expression was .1.23 in either direction. Genes
meeting these criteria were used to generate functional net-
works and pathway analyses with Ingenuity Pathways Anal-
ysis (IPA; Ingenuity Systems, Redwood City, CA, USA).
Spearman’s correlation tests were performed on the gene sets
with a cutoff of 1.2-fold changes in either direction using SPSS
Statistics, version 22.0 software (IBM, Armonk, NY, USA). IPA
was used to generate functional networks and pathways for
the gene sets forwhich expression correlated significantlywith
plasma Se status, and the proteomics dataset and the Com-
parison function in IPA were used to integrate the tran-
scriptomic and proteomic datasets.
RESULTS
Se status of the participants
Participants were selected on the basis of their plasma Se
status and divided into 2 groups that were discordant in
plasmaSe status, butmatched for bodymass index (24.76
0.88 and 24.16 0.72 in suboptimal and optimal Se groups,
respectively), age (53.6 6 2.91 and 54.7 6 3.6, in sub-
optimal and optimal Se groups, respectively), and sex
(5 males, 6 females in each group). The Third National
Health and Nutrition Examination Survey estimated that
the mean serum Se level in the U.S. population is 1.58 mM
(16), a level considered to represent Se adequacy (17). In
contrast, average plasma Se concentration in healthy British
adults was estimated at 1.13 mM (18). The latter concen-
tration is similar to those in other European countries and
is considered suboptimal (5). In the present study, the
group of participants with plasma Se concentrations sim-
ilar to that in the U.S. population, having a mean 6 SEM
plasma Se status concentration of 1.436 0.06 mM (range,
1.25–1.82), a value within the optimal range based on the
hazard ratio for mortality (18) was designated as the op-
timal Se status group. This concentration is well below the
Se concentrations (.2.22 mM) that have been associated
withadversehealth outcomesof high Sedoses observed in
supplementation trials (4, 17, 19). The suboptimal Se status
group corresponds to individuals with a mean 6 SEM
plasma Se status concentration of 0.866 0.01 mM (range,
0.79–0.92), a range that is suboptimal as defined by the
hazard mortality ratio and that has been associated with
increased risk of CRC in women in a large European
population in the EPIC study (5).
Effects of Se status on gene
expression profiles
Both RNA and proteins were extracted from individual
rectal biopsies. Aftermicroarray analysis, differential gene
expression analysis was determined using the RankProd
package and a cutoff of 1.2-fold change showed that 254
genes were differentially expressed between the 2 Se
groups,with 128 genes being up-regulated and 126down-
regulated in the suboptimal Se group compared with the
optimal Se group (for details see Transcript Profiling; http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
token=epkzqgighfujhkh&acc=GSE70550).
Two selenoprotein genes (SEPW1 and SELK) were
down-regulated in the suboptimal Segroup, but theywere
not among the top 25 down-regulated genes. Table 1
presents the top 25genes up- anddown-regulated in rectal
tissue from the suboptimal Se group compared with the
optimal Se group. In the suboptimal Se group, water chan-
nel AQP8, serine protease inhibitor SPINK4, antiapoptotic
factorOLFM4, chloride channelCLCA4, carbonic anhydrase
CA4, and carcinoembryonic antigens CEACAM6 and -7
exhibited the greatest up-regulation. Similarly, other family
members (AQP11,SPINK5, andCEACAM1and-5)werealso
upregulated in the suboptimal Se group. In contrast, HLA-
A29.1, IL1B, the transcription factor CHURC1, antiapoptotic
factors PHDLA1 and IER3, tumor suppressor ERRFI1/Mig6,
and microRNA MIR-221 showed the strongest down-
regulation in the suboptimal Se group comparedwith the
optimal Se group. Real-time PCR confirmed the micro-
array results, with significant correlation observed be-
tween microarray and real-time-PCR expression forMFF
(P = 0.005) and ERRFl1 (P = 0.033) (data not shown).
Ingenuity Pathway Analysis (IPA) was performed on
the microarray dataset to identify biologic functions, ca-
nonical pathways, and networks modulated by Se status
and to predict potential upstream regulators. A large pro-
portion of genes differentially expressed between the 2 Se
groups belonged to cancer [204/254 genes (80%)], gastro-
intestinal diseases (58%), and inflammatory diseases (39%)
categories (Tables 2 and 3).
The cell and molecular functions most affected by Se
status included cellular growth and proliferation, cellular
movement and development, cell death and survival, and
cell-to-cell signaling and interaction (Table 2). The 5 most
significantly affected canonical pathways corresponded to
pathways involved in inflammatory and immune signal-
ing, suggesting an overall down-regulation of immune
response in individuals with suboptimal Se status. IPA
generated 25 networks, among which 19 had at least 10
focus molecules (data not shown), with the 5 most sig-
nificantly affected networks presented in Table 3. As a
result of these changes, IPA predicted that PDGFBB
(P=2.46E236, regulating114genes/254),TNFa (P=3.58E230,
regulating 145 genes/254), and IL1b (P = 3.31E225, reg-
ulating 128 genes/254) are likely to be the most impor-
tant upstream regulators affected by Se status (Table 4).
In addition, most of the identified upstream regulators
(23 of the top 25) are key to immune and inflammatory
responses, and the observed changes indicate that this
response is inhibited by lower Se status. Crosstalk
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between NFkB, TNFa, PDGFBB, and IL1B signaling
pathways (Fig. 3) and between NFkB and other tran-
scription factors, such as p53 and STAT3 (Table 4), has
been described (20). Overall, these results indicate that
genes involved in immune and inflammatory responses,
cell signaling, cell proliferation, tissue and cell mor-
phology, and cellular movement are differentially ex-
pressed in response to Se status.
Correlation of gene expression with Se status
RankProd identified genes that exhibit the highest change
in expression between the 2 Se groups, but did not define
the degree to which gene expression correlated with Se
status. Thus, to further investigate the relationship be-
tween Se status and gene expression, Spearman’s corre-
lation analyses were performed on expression data from
TABLE 3. Most significantly affected networks for the microarray and proteomics datasets
Microarray Proteomics
Network Z score Focus molecules Network Z score Focus molecules
Antimicrobial response, inflammatory
response, cellular movement
35 26 Inflammatory response, cell death and
survival, connective tissue
disorders
38 16
Respiratory system development
and function, carbohydrate
metabolism, cancer
35 26 Cellular development, cell death and
survival, cell cycle
18 9
Cellular growth and proliferation,
hematologic system development and
function, tissue morphology
33 25 Molecular transport, carbohydrate
metabolism, developmental
disorder
3 1
Cancer, organismal injury and
abnormalities, reproductive system
disease
33 25
Cellular development, cellular growth
and proliferation, cell death and
survival
31 24
The most significantly enriched networks are indicated with the z score and number of focus molecules. Networks affected in both
microarray and proteomics datasets are indicated in italics.
TABLE 4. Predicted upstream regulators
Upstream regulator Molecule type
Predicted
activation state Activation z score P of overlap Target molecules in dataset (n)
PDGF BB Complex Inhibited 24.672 2.46E-36 114
TNF Cytokine Inhibited 22.883 3.58E-30 145
IL1B Cytokine Inhibited 22.584 3.31E-25 128
SP1 Transcription regulator 20.808 4.40E-20 101
TREM1 Transmembrane receptor Inhibited 22.593 6.32E-19 128
IL6 Cytokine Inhibited 22.161 7.33E-18 128
IFNG Cytokine 20.682 8.83E-18 121
NFkB (complex) Complex Inhibited 22.275 1.64E-17 143
TGFB1 Growth factor 21.782 2.88E-17 146
CREB1 Transcription regulator Inhibited 22.584 2.25E-16 81
a-Catenin Group 0.895 2.71E-16 49
STAT3 Transcription regulator Inhibited 22.979 5.98E-16 119
IRAK4 Kinase 21.135 9.12E-16 114
IgG Complex 1.833 9.78E-16 126
IL1A Cytokine Inhibited 22.535 1.30E-15 88
PI3K (complex) Complex 0.299 2.43E-15 132
Jnk Group Inhibited 22.736 3.55E-15 135
P38 MAPK Group 21.211 8.03E-15 146
TLR3 Transmembrane receptor 21.318 1.22E-14 129
Cg Complex Inhibited 23.384 2.18E-14 124
TP53 Transcription regulator 21.432 3.38E-14 149
ERK Group Inhibited 22.113 9.28E-14 120
CEBPA Transcription regulator 0.613 1.43E-13 101
RET Kinase Inhibited 22.970 7.22E-13 89
FAS Transmembrane receptor 1.328 8.18E-13 132
IPA upstream transcriptional regulator analysis was performed to identify the cascade of potential upstream regulators that can explain the
observed gene expression changes in the microarray dataset. The most likely regulators are presented, together with the type of molecule, the
number of known targets for each upstream regulator present in the dataset, the predicted z score activation state, the P value of overlap between
genes targeted by each regulator in the dataset, and the genes known to be a target for each upstream regulator.
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all participants for the 254 genes modulated by Se status,
using plasma Se concentration as a continuous variable.
Expression of 69 genes (recognized by 75 different gene
probes) correlated significantlywith Se status, of which 34
correlated positively and 35 correlated negatively (Sup-
plemental Table S1 and Fig. 1). Expression of the 2 sele-
noprotein genes SELW and SELK, identified as being
down-regulated in the suboptimal Se group, showed a
strong positive correlation with Se status (rSelw = 0.637;
P = 0.001, and rSelk = 0.474; P = 0.026). Expression of
DNAJC12, a member of the DnaJ/Hsp40 family acting as a
cochaperone with Hsp70 and involved in protein folding
and export (21); antisense RNA SNHG6; and SEPW1
showed the strongest positive correlations with Se concen-
tration.Hsp70 is involved in nonsense-mediated decay (22)
andhasbeen involved in the control of selenoproteinmRNA
degradation in conditions of low Se status (23). In contrast,
expression of acyl-coenzyme A oxidase ACOX1, the first
enzyme in peroxisomal fatty acid b-oxidation, strongly
negatively correlated with Se status. Because ACOX1 acti-
vates NFkB (24), negative correlation of ACOX1 expression
with Se status could contribute to the observed NFkB in-
hibition. Moreover, NUAK2, which is regulated by NFkB
and is involved in actin cytoskeleton remodelling (25), and
ACTB,ALDOA,SLC9A3R1,MYH9,DYNLRB1, andTUBAL3,
whichare implicatedincytoskeletonorganization(26,27),had
expression that correlated strongly with Se status.
Subsequently, pathway analysis of the 69 genes for
which expression correlated strongly with Se status
revealed that the most affected diseases and disor-
ders correspond to the cancer and cancer and tu-
morigenesis subcategories (34 molecules/69; 49%;
P = 1.71E205–4.93E202) and to inflammatory response
(18 molecules/69; 26%; P = 4.88E205–4.67E202). Three
main networks identified were: 1) cancer, organismal
injury, and abnormalities, reproductive system disease
(21 focusmolecules, z score 45), centered aroundNFkB; 2)
cellular function and maintenance carbohydrate metab-
olism, small-molecule biochemistry (16 focusmolecules, z
score 31), centered around TNF; and 3) hematologic dis-
ease, cellular growth and proliferation, cellular develop-
ment (9 focusmolecules, z score 15) centered aroundTP53
(Supplemental Fig. S1). Supporting these observations,
inhibition of sequestosome 1 (SQSTM1), which regulates
TNF-driven activation of NFkB, was identified as the
most significant upstream regulator (P = 2.50E206), fol-
lowed by PLK2 and IL13, also involved in NFkB regula-
tion, the second and third most significant (P = 4.09E205
and P = 4.61E205, respectively). Overall, these results in-
dicate that geneswhose expression correlatewith Se status
play a key role in inflammatory pathways, with a central
role for NFkB and TNF.
Effects of Se status on proteomics profiles
Proteomic profiles from whole rectal biopsies were
characterized by 2-D gel electrophoresis, followed by
in-gel trypsin digestion and MALDI-ToF MS. To limit
the bias normally associated with proteomic analysis
when the analysis is restricted toward the more
abundant proteins, analysis was performed on all
220 spots that were identified by MS. Of these 220, 36
spots, corresponding to 26 individual proteins, were
differentially expressed between the suboptimal Se
and optimal Se status groups (Table 5). They include a
substantial proportion [13/36 spots; 7/26 (; 26%)
proteins] of cytoskeleton proteins: 1) 4 cytokeratins
and desmin, 2) actin ACTA2, and 3) tubulin TUBA1B.
In addition, 4 proteins known to be involved in the
Figure 1. Correlation of gene expression with plasma Se concentration. Spearman’s correlation was performed on the gene set
generated by microarray analysis, to identify expression of genes that significantly correlate with plasma Se concentration.
Scatterplots show the relationship between gene expression and Se status for genes with the strongest negative (A) or
positive (B) correlation coefficient. A list of genes with expression significantly correlated with Se status is presented in
Supplemental Table S1.
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cytoskeletal organization, SS18, S100A9, SFN, and
HSP90B, exhibited differential expression between
the 2 Se groups. These observations suggest that
cytoskeleton remodelling is a major signature of
Se effects in rectal tissue. All cytoskeletal proteins
and associated factors were up-regulated in the
suboptimal Se group compared with the optimal Se
group, apart from 1 spot corresponding to cytokeratin
8 and S100A9.
Additional proteins differentially expressed between
the 2 Se groups (Table 5) include: 1) proteins involved in
immune and inflammatory response (tumor rejection
antigen GP96 (HSP90B1), complement component C3,
glycyl-tRNA synthetase (28) and calcium-binding protein
S100A9); 2) proteins involved in lipid metabolism and
disruption of cholesterol homeostasis known to be linked
to inflammatory processes (29) and to affect signal trans-
duction and membrane trafficking (29) (FABP5, apolipo-
protein A1, StAR-related lipid transfer protein); and 3)
proteins involved in antioxidant mechanisms, including
glutathione S-transferase v 1 (GSTO1), S100A9, and al-
bumin. The lowered expression of these genes in the
TABLE 5. Proteins differentially expressed in suboptimal and optimal Se groups
Symbol
Entrez
gene name
UniProt/
Swiss-Prot
accession
Fold
change P Network Location Type
Optimal Se group
HBB Hemoglobin, b P68871 2.287862 1.57E-02 1 Cytoplasm Transporter
KRT9 Keratin 9 P35527 2.136131 3.99E-02 Other Other
TUBA1B Tubulin, a 1b B3KPS3 1.649467 7.15E-03 2 Cytoplasm Other
HSP90B1 Heat shock protein 90 kDa
b (Grp94), member 1
P14625 1.60214 1.94E-02 1,2 Cytoplasm Other
LAP3 Leucine aminopeptidase 3 P28838 1.566994 1.66E-02 2 Cytoplasm Peptidase
KRT19 Keratin 19 P08727 1.561573 1.17E-03 1 Cytoplasm Other
SS18 Synovial sarcoma
translocation,
chromosome 18
Q15532 1.536875 1.20E-02 2 Nucleus Transcription
regulator
STARD4 Star-related lipid
transfer (START)
domain containing 4
Q96DR4 1.461044 2.55E-02 1 Cytoplasm Transporter
KRT10 Keratin 10 P13645 1.417157 2.15E-03 1 Cytoplasm Other
ACTA2 Actin, a 2, smooth
muscle, aorta
P62736 1.355664 4.27E-02 1 Cytoplasm Other
SFN Stratifin P31947 1.250929 4.12E-02 2 Cytoplasm Other
DES Desmin P17661 1.249196 4.81E-02 1 Cytoplasm Other
FABP5 Fatty acid binding protein
5 (psoriasis-associated)
Q01469 1.164734 4.86E-02 1 Cytoplasm Transporter
Suboptimal Se group
GALE UDP-galactose-4-epimerase Q14376 0.853818 4.49E-02 3 Cytoplasm Enzyme
SERPINC1 Serpin peptidase inhibitor,
clade C (antithrombin),
member 1
P01008 0.789494 1.09E-02 1 Extracellular
space
Enzyme
GARS Glycyl-tRNA synthetase P41250 0.783497 4.30E-02 2 Cytoplasm Enzyme
A2ML1 a-2–Macroglobulin-like 1 A8K2U0 0.782412 3.50E-02 Cytoplasm Other
HPX Hemopexin P02790 0.757333 2.35E-02 1 Extracellular
space
Transporter
S100A9 S100 calcium binding
protein A9
P06702 0.747425 1.00E-02 1 Cytoplasm Other
APOA1 Apolipoprotein A-I P02647 0.746389 3.93E-02 1 Extracellular
space
Transporter
G6PD Glucose-6-phosphate
dehydrogenase
P11413 0.716481 5.06E-03 1 Cytoplasm Enzyme
ALB Albumin P02768 0.712025 3.30E-02 1, 2 Extracellular
space
Transporter
GSTO1 Glutathione
S-transferase v 1
P78417 0.68968 7.87E-03 2 Cytoplasm Enzyme
KRT8 Keratin 8 P05787 0.625898 2.22E-02 1 Cytoplasm Other
C3 complement component 3 B4E216 0.622869 1.59E-02 1 Extracellular
space
Peptidase
F13A1 coagulation factor
XIII, A1 polypeptide
P00488 0.59791 1.97E-02 2 Extracellular
space
Enzyme
After, 2-D gel electrophoresis, proteins were identified by MALDI/ToF MS. Differentially expressed proteins between the 2 Se
groups are presented, together with their UniProt (http://www.uniprot.org) identification (ID), and the P value and fold change
estimated from 2-D gel quantification.
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suboptimal Se group not only suggests a reduced immu-
nity and capacity to protect against oxidative damage, but
is compatible with the links between glutathione and Se
metabolism.Moreover, the cytoskeleton, akeymediatorof
immune and inflammatory processes (30, 31), is highly
sensitive to oxidative stress (32).
IPA analysis of the proteomic data also predicted
activation of cancer pathways (z score activation, 2.575;
P = 2.89E209; focus molecules, 21) in individuals with
suboptimal Se status. Consistent with observations
from RNA expression analysis by microarray, immu-
nologic and inflammatory responses biologic func-
tions and networks, together with cell death and
survival, cellular movement and development, cell
growth and differentiation, and hematologic system
and molecular transport (Table 2) were among the
most affected by Se status. IPA identified 3 networks,
with network 1, centered around NFkB (focus mole-
cules, 16; z score 38), representing the most important
one (Table 3).
Integrated transcriptomics and proteomics
Tables 2 and 3 summarize the pathways and networks
altered by Se status in transcriptomic and proteomic
datasets. To integrate the 2 approaches, the datasets
were combined, and IPA was used to identify biologic
processes or pathways in which features from both
transcripts and proteins are enriched. Twenty-eight
networks were identified, and the interconnection be-
tween proteomic and transcriptomic networks was
analyzed. Proteomic network 1 is connected to 8 net-
works from the microarray dataset, and proteomic
network 2 is connected to 6 microarray networks.
Merging proteomic network 1 (p 1) with individual
connected microarray networks (4–7 and 10 m) re-
vealed NFkB to be the central node of these merged
networks (Fig. 2) and IL1, TNF, and Akt to be the
central nodes of merged networks 1-1, 1-18, and 1-12,
respectively (data not shown). On the other hand, the
proto-oncogenes c-Myc, c-Fos and b-catenin were
identified as central nodes from merging proteomic
network 2, with connected microarray networks 2 and
8, 4, and 6 (data not shown).
DISCUSSION
This study is the first to integrate transcriptomic and
proteomic approaches for assessing the effects of
physiologic differences in status of the dietary anti-
oxidant Se on events in the large-bowel mucosa in
healthy individuals. Using this approach, we report
that the expression of factors implicated in inflam-
matory signaling, immune function, and cytoskel-
eton remodelling is altered in individuals with
suboptimal Se status in healthy human rectal mucosa,
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Figure 2. Interconnection between networks identified from proteomic and transcriptomic datasets. A) IPA analysis
performed on the combined proteomic and transcriptomic datasets revealed 28 networks, corresponding to 25 microarray
networks (white background) and 3 proteomic networks (dark gray background). Connections between these networks
are represented by lines. Figures adjacent to the lines indicate the number of common genes shared between pathways.
Major proteomic networks 1 and 2 are interconnected and showed connections with 8 and 6 microarray networks,
respectively. This information was used to identify central regulatory nodes for interconnected networks. B) With this
approach, NFkB was identified as a common central node for 5 of 8 merged networks involving proteomic network 1 (1 p)
and microarray network (4–7 and 10 m). The Venn diagram presents the number of molecules shared by these merged
networks.
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providing novel insights into the mechanisms through
which Se may influence cancer risk and colorectal
function. Crosstalk between these pathways is funda-
mental to the maintenance of gut homeostasis through
a partnership among the gut epithelium, immune cells,
and responses to bacteria (33). Among the genes and
proteins exhibiting the strongest change in expression
between the 2 Se groups (Tables 1 and 5), many have
been shown to have altered expression in colorectal
adenomas.
As expected differences in selenoprotein mRNA
expression were observed between the 2 groups,
with significant reduction of both selenoprotein W
[fold change (FC) = 21.404] and selenoprotein K
(FC = 21.286) in the suboptimal group (Gene Expression
Omnibus repository, GSE70550; http://www.ncbi.nlm.nih.
gov/geo/). Moreover, expression of both SEPW1 and SELK
correlated strongly with Se status (Supplemental Table S1),
consistentwith the responsiveness of selenoproteins toSe in
the colon. It is known that identification of selenoproteins
using MS is problematic, and it is therefore not surprising
that our proteomic analysis did not identify specific
selenoproteins.
We observed significant effects of Se status on im-
mune and inflammatory signaling in both the microarray
and proteomics datasets (Table 2), with approximately a
third of identified genes (80/254) and proteins (7/26) in-
volved in immune cell trafficking, with most canonical
pathways associated with inflammation, and with in-
flammatory and immune diseases and inflammatory
Figure 3. Hypothetical model illustrating the integration of observed effects of suboptimal Se status on colorectal function.
This model illustrates how the observed changes in gene expression and protein levels affect inflammatory and immune
signaling, cytoskeletal remodelling and apoptotic/survival pathways, and how these changes and crosstalk between these
pathways have the potential to contribute to tissue dysplasia in the rectum of an individual with suboptimal Se status. In
the healthy colorectal epithelium, NFkB plays a critical role of coordinator, regulating: 1) cytokine and chemokine
production (blue circle) in response to the gut bacteria (blue rectangles), 2) the recruitment of immune cells (red, yellow,
and beige) to the epithelium to ensure immuno-surveillance, and 3) the regulation of the balance between survival and
apoptotic factors. We propose that NFkB inhibition, as a result of suboptimal Se status, reduces immune and inflammatory
signaling and induces cytoskeleton remodelling (changes associated with suboptimal Se are indicated in red and dotted
lines). Cytoskeletal alteration and imbalance of apoptotic/survival signals could result in epithelial barrier damage and
changes in cell and tissue morphology and cell movement. Moreover, the combined alteration of the epithelial barrier,
reduced expression of IL1B and IL8, and reduced immunity could favor bacterial invasion, leading to chronic
inflammation.
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response among the top biologic functions and net-
works in both datasets. Genes exhibiting the largest
fold changes in expression included those involved in
the immune response (HLA-A29.1 and HLA-DRB1),
growth factors and cytokines (BMP4, CCL19, CCL12,
IL1B, and IL8), genes previously reported to be associ-
ated with either inflamed colonic epithelium [OLFM4
(34) and SPINK4 (35, 36)] or colorectal cancer [AQP8
and OLFM4 (37, 38)], and tumor suppressor genes
[ERRFI1 and PHLDA1 (39)] (Table 1). Furthermore, a
large number of proteins identified by proteomics
are key players in inflammation and immune function
(e.g., ApoA1, Serpin C1, S1009, C3, HPX, HSP90B1, and
G6PD). Integrating the 2 datasets identified NFkB, IL1,
TNF, and Akt, which play key roles in inflammation, as
central nodes of merged networks (Fig. 2B). Moreover,
most of the highly significant predicted upstream reg-
ulators were cytokines and growth factors involved in
inflammation and immune response (Table 4). Pathway
analysis of genes for which expression correlated sig-
nificantly with Se status highlighted the central regu-
latory role of NFkB and TNFa. SELK expression, which
correlated positively with Se status (Supplemental Ta-
ble S1), has been identified recently as a key player in
the immune response and in calcium signaling path-
ways (40, 41). Thus, overall pathway and network
analysis was consistent with both a reduction of in-
flammatory signaling capacity and inhibition of NFkB
and proinflammatory cytokines TNFa and IL1B in
rectal tissue of individuals with suboptimal Se status.
Because NFkB plays a central role in coordinating the
response to gut microflora and the inflammatory sig-
naling response, we propose that inadequate Se status
results in disruption of the coordination by NFkB of
immune and inflammatory responseswith thepotential
to contribute to the transformation process (Fig. 3).
This theory is supported by previous observations
that NFkB signaling and inflammatory response
pathways were altered in the colon of mice fed a diet
marginally deficient in Se (13, 42), and inhibition of
NFkB signaling in epithelial cells leads to sponta-
neous development of severe inflammatory condi-
tions in mice (43). Dysregulation of immune and
inflammatory functions are central to colorectal car-
cinogenesis (20).
Proteomic data indicated that relatively small dif-
ferences in Se status were associated with changes in
abundance of a substantial proportion of cytoskeletal
proteins, including cytokeratins, desmin, actin, and
tubulin (Table 5). Cytokeratins have key regulatory
functions, and actin microfilaments maintain the in-
tegrity of the epithelial barrier and cell polarity (44).
Consequently, cellular movement, growth and pro-
liferation and tissue morphology were among the
most affected biologic functions identified by IPA
(Table 2). Consistent with these observations, the
same biologic functions were affected significantly at
the mRNA level (Table 2). This finding suggests the
potential for substantial remodelling of the cytoskel-
eton in rectal mucosa in response to suboptimal Se
status. This processwould be expected to a havemajor
impact on the colonic epithelium as it undergoes
normal cycles of proliferation, migration, and differ-
entiation. Indeed, previous work has found altered
expression of cytoskeletal components in CRC; des-
moglein 2 and cytokeratins KRT18, KRT6A, and
KRT8 were identified as signatures of CRC subtypes
(45), high expression of desmin was associated with
CRC and cytokeratins 8, 10, 18, and 19 and b-actin
were up-regulated in CRC tumors (46). In addition, pre-
vious work has indicated a role for the cytoskeleton in
mediating the immune and inflammatory responses
(30, 31).
In the present study, both RNA and proteins were
extracted from rectal biopsy tissues, which are complex
with multiple cell types and at different stages of dif-
ferentiation. Therefore the results reflect changes in
protein and RNA profiling from diverse cell types of
both epithelial and immune origin, and changes in the
proportions of these 2 major cell types may account for
some of the observed effects. However, we have no
reason to believe that there are any systematic differ-
ences in cellularity of the biopsies between those with
normal and suboptimal Se status, and this complexity
takes into account the different cellular actors present in
the rectal mucosa.
Overall, the present data indicate that, in the mac-
roscopically normal rectal mucosa, suboptimal Se
status is associated with alterations in cytoskeleton
remodelling and reduced inflammatory and immune
signaling capacity. This finding suggests that the in-
flammatory response and the capacity to recruit im-
mune cells are reduced in the rectum of individuals
with suboptimal Se status. Colorectal cancer is char-
acterized by derangements in immune and inflam-
matory signaling and cytoskeleton alterations. We
hypothesize that suboptimal Se status has the poten-
tial to compromise an individual’s redox capacity
and ability to mount appropriate immune and in-
flammatory responses to exogenous, physiologic, or
microbiological stressors and, as a result, could favor
the development of cancer (Fig. 3). In support of this
hypothesis, cancer pathways were identified as the
most affected pathways in both proteomic and tran-
scriptomic datasets. Recent evidence from genetic
association studies has led to the hypothesis of a con-
vergence of hormones, inflammation, and energy-
related factors (CHIEF) pathway in the etiology of
CRC (29). We propose that the convergence of reduced
immunity and inflammatory response and cytoskele-
ton remodelling associated with reduced Se status
would increase CRC risk.
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